Balversa (Erdafitinib) Patent Expiration, LOE Window & CMS Spending

Balversa (Erdafitinib) by Johnson & Johnson: FDA Orange Book core substance LOE 2033-04-12 (last listed 2038-02-02), 0 AB generics, $27.0M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN212018 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-04-12
Last Listed Patent or Exclusivity Date2038-02-02
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$27.0M
2024 Medicare Part D Spend$22.7M
2024 Medicaid Spend$4.3M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 22.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.